{
  "trial_id": "NCT03826472",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, duration of type 2 diabetes, baseline fasting glucose levels, body mass index (BMI), HbA1c levels, use of oral antihyperglycemic agents, dietary habits, physical activity levels, baseline lipid profile, baseline blood pressure, smoking status, alcohol consumption.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Mean duration of diabetes",
          "duration of type 2 diabetes"
        ],
        [
          "Home self-monitoring of blood glucose prior to study start",
          "baseline fasting glucose levels"
        ],
        [
          "Medication use",
          "use of oral antihyperglycemic agents"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "HbA1c levels",
        "dietary habits",
        "physical activity levels",
        "baseline lipid profile",
        "baseline blood pressure",
        "smoking status",
        "alcohol consumption"
      ]
    },
    "processed-gen-response": "Age, gender, duration of type 2 diabetes, baseline fasting glucose levels, body mass index (BMI), HbA1c levels, use of oral antihyperglycemic agents, dietary habits, physical activity levels, baseline lipid profile, baseline blood pressure, smoking status, alcohol consumption."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Body Mass Index, Duration of Type 2 Diabetes, Baseline Fasting Glucose, Use of Oral Antihyperglycemic Agents, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Mean duration of diabetes",
          "Duration of Type 2 Diabetes"
        ],
        [
          "Home self-monitoring of blood glucose prior to study start",
          "Baseline Fasting Glucose"
        ],
        [
          "Medication use",
          "Use of Oral Antihyperglycemic Agents"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Body Mass Index, Duration of Type 2 Diabetes, Baseline Fasting Glucose, Use of Oral Antihyperglycemic Agents"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "##Answer:\nAge, Continuous, Sex: Female, Male, Diabetes duration, Body Mass Index, Fasting blood glucose, HbA1c, Antihyperglycemic agent use,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Mean duration of diabetes",
          "Diabetes duration"
        ],
        [
          "Home self-monitoring of blood glucose prior to study start",
          "Fasting blood glucose"
        ],
        [
          "Medication use",
          "Antihyperglycemic agent use"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "HbA1c"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Diabetes duration, Body Mass Index, Fasting blood glucose, HbA1c, Antihyperglycemic agent use"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, body mass index (BMI), duration of type 2 diabetes, type and dose of oral antihyperglycemic agent, average daily blood glucose levels, HbA1c, systolic and diastolic blood pressure, lipid profile, smoking history, physical activity level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Mean duration of diabetes",
          "duration of type 2 diabetes"
        ],
        [
          "Home self-monitoring of blood glucose prior to study start",
          "average daily blood glucose levels"
        ],
        [
          "Medication use",
          "type and dose of oral antihyperglycemic agent"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "HbA1c",
        "systolic and diastolic blood pressure",
        "lipid profile",
        "smoking history",
        "physical activity level."
      ]
    },
    "processed-gen-response": "Age, sex, body mass index (BMI), duration of type 2 diabetes, type and dose of oral antihyperglycemic agent, average daily blood glucose levels, HbA1c, systolic and diastolic blood pressure, lipid profile, smoking history, physical activity level."
  }
}